|
1.
|
Shaw NJ, Georgopoulos NT, Southqate J and
Trejdosiewicz LK: Effect of loss of p53 and p16 function on life
span and survival of human urothelial cells. Int J Cancer.
116:634–639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Le Frère-Belda MA, Gil Diez de Medina S,
Daher A, Martin N, Albaud B, Heudes D, Abbou CC, Thiery JP, Zafrani
ES, Radvanyi F and Chopin D: Profiles of the 2 INK4a gene products,
p16 and p14ARF, in human reference urothelium and bladder
carcinomas, according to pRb and p53 protein status. Hum Pathol.
35:817–824. 2004.PubMed/NCBI
|
|
3.
|
Wu Q, Possati L, Montesi M, Gualandi F,
Rimessi P, Morelli C, Trabanelli C and Barbanti-Brodano G: Growth
arrest and suppression of tumorigenicity of bladder-carcinoma cell
lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci
on human chromosome 9. Int J Cancer. 65:840–846. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Chatterjee SJ, George B, Goebell PJ,
Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar
RH and Cote RJ: Hyperphosphorylation of pRb: a mechanism for RB
tumour suppressor pathway inactivation in bladder cancer. J Pathol.
203:762–770. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kondo E, Seto M, Yoshikawa K and Yoshino
T: Highly efficient delivery of p16 antitumor peptide into
aggressive leukemia/lymphoma cells using a novel transporter
system. Mol Cancer Ther. 3:1623–1630. 2004.PubMed/NCBI
|
|
6.
|
Sylvester RJ, van der Meijden AP and Lamm
DL: Intravesical bacillus Calmette-Guerin reduces the risk of
progression in patients with superficial bladder cancer: a
meta-analysis of the published results of randomized clinical
trials. J Urol. 168:1964–1970. 2002. View Article : Google Scholar
|
|
7.
|
Kondo E, Tanaka T, Miyake T, Ichikawa T,
Hirai M, Adachi M, Yoshikawa K, Ichimura K, Ohara N, Moriwaki A,
Date I, Ueda R and Yoshino T: Potent synergy of dual antitumor
peptides for growth suppression of human glioblastoma cell lines.
Mol Cancer Ther. 7:1461–1471. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Fåhraeus R, Laín S, Ball KL and Lane DP:
Characterization of the cyclin-dependent kinase inhibitory domain
of the INK4 family as a model for a synthetic tumour suppressor
molecule. Oncogene. 16:587–596. 1998.PubMed/NCBI
|
|
9.
|
Arvanitis DA and Spandidos DA:
Deregulation of the G1/S phase transition in cancer and squamous
intraepithelial lesions of the uterine cervix: A case control
study. Oncol Rep. 20:751–760. 2008.PubMed/NCBI
|
|
10.
|
Simoneau AR, Spruck CH III,
Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven
K, Horn T and Jones PA: Evidence for two tumor suppressor loci
associated with proximal chromosome 9p to q and distal chromosome
9q in bladder cancer and the initial screening for GAS1 and PTC
mutations. Cancer Res. 56:5039–5043. 1996.
|
|
11.
|
Wolf JK, Kim TE, Fightmaster D, Bodurka D,
Gershenson DM, Mills G and Wharton JT: Growth suppression of human
ovarian cancer cell lines by the introduction of a p16 gene via a
recombinant adenovirus. Gynecol Oncol. 73:27–34. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Nakazawa K, Murata S, Yuminamochi T, Ishii
Y, Ohno S, Nakazawa T, Kondo T and Katoh R: p16(INK4a) expression
analysis as an ancillary tool for cytologic diagnosis of urothelial
carcinoma. Am J Clin Pathol. 132:776–784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Asamoto M, Hori T, Baba-Toriyama H, Sano
M, Takahashi S, Tsuda H and Shirai T: p16 gene overexpression in
mouse bladder carcinomas. Cancer Lett. 127:9–13. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Knowles MA: Molecular pathogenesis of
bladder cancer. Int J Clin Oncol. 13:287–297. 2008. View Article : Google Scholar
|
|
15.
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP,
Roychowdhury DF, Tomlin I, Visseren-Grul CM and Conte PF:
Gemcitabine and cisplatin versus methotrexate, vinblastine,
doxorubicin, and cisplatin in advanced or metastatic bladder
cancer: results of a large, randomized, multinational, multicenter,
phase III study. J Clin Oncol. 18:3068–3077. 2000.
|
|
16.
|
Sato M, Yanai H, Morito T, Oda W, Shin-no
Y, Yamadori I, Tshushima T and Yoshino T: Association between the
expression pattern of p16, pRb and p53 and the response to
intravesical bacillus Calmette-Guerin therapy in patients with
urothelial carcinoma in situ of the urinary bladder. Pathol Int.
61:456–460. 2011. View Article : Google Scholar
|
|
17.
|
Horiguchi Y, Kikuchi E, Ozu C, Nishiyama
T, Oyama M, Horinaga M, Yoshioka K and Tachibana M: Establishment
of orthotopic mouse superficial bladder tumor model for studies on
intravesical treatments. Hum Cell. 21:57–63. 2008. View Article : Google Scholar : PubMed/NCBI
|
